<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025476</url>
  </required_header>
  <id_info>
    <org_study_id>AFM1713D1</org_study_id>
    <nct_id>NCT04025476</nct_id>
  </id_info>
  <brief_title>Immune Profile of Acute VKH Patients PBMC</brief_title>
  <acronym>IPV</acronym>
  <official_title>Clinical Observational Research on Changes of Peripheral Blood Mononuclear Cell（PBMC） Immunity and Expression Profile in Peripheral Blood of Different Course of of Vogt-Hoyanagi-Harada（VKH） Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aier School of Ophthalmology, Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aier School of Ophthalmology, Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will collect blood samples of different courses of VKH patients for
      investigating immune profile, observe major immune cells number ,functional and membrane
      molecular changes in the course of treatment, to investigate pathogenesis of VKH. Meanwhile,
      the investigators will collect clinical data of VKH patients to observe choroid and retina
      change in different courses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2019</start_date>
  <completion_date type="Anticipated">July 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T/B /NK(natural killer )/monocyte...etc, cell numbers of blood samples in VKH patients</measure>
    <time_frame>one year</time_frame>
    <description>use flow cytometry to count T/B /NK/monocyte...etc, cell numbers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T/B /NK/monocyte...etc cell subtype proportion in blood samples in VKH patients</measure>
    <time_frame>one year</time_frame>
    <description>use flow cytometry to measure T/B /NK/monocyte...etc cell subtype proportion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T/B /NK/monocyte...etc cell functional change in VKH patients</measure>
    <time_frame>one year</time_frame>
    <description>use ELISA(enzyme linked immunosorbent assay) to measure inflammatory cytokines level in peripheral blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>choroid and retinal thickness change in different course of VKH patients</measure>
    <time_frame>one year</time_frame>
    <description>Use OCT（optical coherence tomography） to measure choroid and retina thickness changes in macular zone of different course VKH patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use OCTA(optical coherence tomography angiography) to measure macular and optic disc vascular index</measure>
    <time_frame>one year</time_frame>
    <description>Use OCTA to measure macular and optic disc vascular index in different course VKH patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use Maia perimeter to measure macular integrality</measure>
    <time_frame>one year</time_frame>
    <description>Use Maia perimeter to measure macular integrality including light threshold and central fixation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure the Injury degree of choroid and retinal vessels</measure>
    <time_frame>one year</time_frame>
    <description>Use FFA(fluorescein fundus angiography)/ICG(Indocyanine Green Angiography) to measure the Injury degree of choroid and retinal vessels</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>VKH Syndrome</condition>
  <arm_group>
    <arm_group_label>VKH patients</arm_group_label>
    <description>acute VKH patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>health people age/sex match to the VKH patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>IV and oral steroids</description>
    <arm_group_label>VKH patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample of VKH patients
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        acute primary VKH patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute VKH patients, meet a criterion of VKH, no recurrence.

          2. Age range from 18 to 50 years old.

        Exclusion Criteria:

          1. Patients with Severe Cardiovascular and Cerebrovascular Diseases

          2. Patients allergic to steroid or contrast agents;

          3. A history of ocular trauma or intraocular surgery within 3 months; Vaccinated; History
             of infectious diseases

          4. having a history of heredity, immune system correlation, neuroendocrine and digestive
             system diseases

          5. Patients who take health care products for a long time and have heavy alcohol and
             tobacco addiction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Zhang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Central-southern university, Aier ophthalmology colleage</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaohui Li, Ph.D/MD</last_name>
    <phone>+86-186-2790-1441</phone>
    <email>lizhaohui@whu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yafei Huang, Ph.d</last_name>
    <phone>+86-136-2862-7928</phone>
    <email>huangyf@tjh.tjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wuhan Aier eye hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430064</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Li, Ph.D/MD</last_name>
      <phone>+86-186-2790-1441</phone>
      <email>lizhaohui@whu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yafei Huang, Ph.D</last_name>
      <phone>+86-136-28627928</phone>
      <email>huangyf@tjh.tjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VKH; immune profile;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

